MA38175A1 - Lactames fusionnés à un aryle et hétéroaryle - Google Patents

Lactames fusionnés à un aryle et hétéroaryle

Info

Publication number
MA38175A1
MA38175A1 MA38175A MA38175A MA38175A1 MA 38175 A1 MA38175 A1 MA 38175A1 MA 38175 A MA38175 A MA 38175A MA 38175 A MA38175 A MA 38175A MA 38175 A1 MA38175 A1 MA 38175A1
Authority
MA
Morocco
Prior art keywords
heteroaryl
aryl
compounds
salts
lactams
Prior art date
Application number
MA38175A
Other languages
English (en)
Other versions
MA38175B1 (fr
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA38175A1 publication Critical patent/MA38175A1/fr
Publication of MA38175B1 publication Critical patent/MA38175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des composés de formule générale (i), des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques contenant lesdits composés et sels, et des méthodes d'utilisation desdits composés, sels et compositions pour traiter une croissance cellulaire anormale, y compris le cancer. Dans la formule générale (i), r
MA38175A 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle MA38175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
PCT/IB2013/060682 WO2014097041A1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Publications (2)

Publication Number Publication Date
MA38175A1 true MA38175A1 (fr) 2018-08-31
MA38175B1 MA38175B1 (fr) 2018-11-30

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38175A MA38175B1 (fr) 2012-12-21 2013-12-05 Lactames fusionnés à un aryle et hétéroaryle

Country Status (46)

Country Link
US (3) US9040515B2 (fr)
EP (2) EP3339303B9 (fr)
JP (1) JP5909308B2 (fr)
KR (1) KR101712441B1 (fr)
CN (1) CN104870435B (fr)
AP (1) AP2015008574A0 (fr)
AR (1) AR094174A1 (fr)
AU (1) AU2013365908C1 (fr)
BR (1) BR112015014678B1 (fr)
CA (1) CA2893339C (fr)
CL (1) CL2015001733A1 (fr)
CR (2) CR20200273A (fr)
CU (1) CU24414B1 (fr)
CY (2) CY1119883T1 (fr)
DK (2) DK2935238T3 (fr)
DO (1) DOP2015000157A (fr)
EA (1) EA028317B1 (fr)
EC (1) ECSP15031579A (fr)
ES (2) ES2658974T3 (fr)
GE (1) GEP201706718B (fr)
GT (1) GT201500190A (fr)
HR (2) HRP20180060T1 (fr)
HU (2) HUE050009T2 (fr)
IL (1) IL239520B (fr)
LT (2) LT3339303T (fr)
MA (1) MA38175B1 (fr)
MD (1) MD4664C9 (fr)
ME (2) ME03793B (fr)
MX (2) MX2015008058A (fr)
MY (2) MY176307A (fr)
NO (1) NO2961649T3 (fr)
NZ (1) NZ708801A (fr)
PE (1) PE20151090A1 (fr)
PH (1) PH12015501367B1 (fr)
PL (2) PL2935238T3 (fr)
PT (2) PT3339303T (fr)
RS (2) RS56815B1 (fr)
SG (1) SG11201504076XA (fr)
SI (2) SI3339303T1 (fr)
TN (1) TN2015000281A1 (fr)
TR (1) TR201802791T4 (fr)
TW (1) TWI546293B (fr)
UA (1) UA111305C2 (fr)
UY (2) UY38712A (fr)
WO (1) WO2014097041A1 (fr)
ZA (1) ZA201504437B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075084A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014151142A1 (fr) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
WO2015023915A1 (fr) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (fr) * 2014-06-17 2015-12-23 Pfizer Inc. Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
CN107148419A (zh) * 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
EP3236962A2 (fr) 2014-12-23 2017-11-01 University of Copenhagen Traitement du cancer par inhibition de l'activité de l'ezh2
PL3274343T3 (pl) * 2015-03-27 2020-08-10 Syngenta Participations Ag Mikrobiocydowe pochodne heterobicykliczne
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2017084494A1 (fr) 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 Dérivé du benzofurane, son procédé de préparation et son utilisation en médecine
MX2018013519A (es) * 2016-05-05 2019-03-14 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2.
EP3529242A1 (fr) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
MY198008A (en) 2017-05-18 2023-07-25 Jiangsu Hengrui Medicine Co Crystal of benzofuran derivative free base and preparation method
TWI810185B (zh) 2017-05-18 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｅｚｈ２抑制劑與ｂｔｋ抑制劑聯合在製備治療腫瘤的藥物中的用途
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
NZ766447A (en) 2018-01-31 2021-12-24 Mirati Therapeutics Inc Prc2 inhibitors
EP4155293B1 (fr) * 2018-06-07 2025-07-30 The Regents of The University of Michigan Inhibiteurs de prc1 et méthodes de traitement comprenant ces derniers
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
EP3870173A4 (fr) * 2018-10-24 2022-06-22 Vanderbilt University Modulateurs et inhibiteurs de wdr5
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
JP7624404B2 (ja) 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
US12577227B2 (en) 2019-06-04 2026-03-17 Vanderbilt University WDR5 inhibitors and modulators
AU2020288563A1 (en) 2019-06-05 2022-01-06 Mirati Therapeutics, Inc. Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer
JP7387907B2 (ja) 2020-08-13 2023-11-28 ハンミ ファーマシューティカル カンパニー リミテッド 新規なジオキソロイソキノリノン誘導体化合物及びその用途｛ｎｏｖｅｌ ｄｉｏｘｏｌｏｉｓｏｑｕｉｎｏｌｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
CN116457348B (zh) * 2021-02-26 2024-11-26 南京迈晟科技有限责任公司 Ezh2抑制剂及其用途
EP4634152A1 (fr) 2022-12-15 2025-10-22 Syngenta Crop Protection AG Nouveaux composés bicycliques-carboxamide utiles en tant que pesticides
CN118978498B (zh) * 2024-10-22 2025-04-01 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8536179B2 (en) 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
WO2011140325A1 (fr) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
WO2012068589A2 (fr) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
EP3323820B1 (fr) * 2011-02-28 2023-05-10 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2893843C (fr) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Composes de carbamoylpyridone polycycliques et leur utilisation pharmaceutique
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CN104870466B (zh) 2012-12-21 2018-05-18 霍夫曼-拉罗奇有限公司 作为催产素激动剂的肽
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
DK2935238T3 (en) 2018-01-22
CA2893339A1 (fr) 2014-06-26
RS60582B1 (sr) 2020-08-31
US20150175572A1 (en) 2015-06-25
ZA201504437B (en) 2016-07-27
SI3339303T1 (sl) 2020-09-30
EA028317B1 (ru) 2017-11-30
EP3339303A1 (fr) 2018-06-27
HRP20201194T1 (hr) 2020-11-13
CR20200273A (es) 2020-09-23
CR20150279A (es) 2015-09-03
GT201500190A (es) 2016-01-21
JP5909308B2 (ja) 2016-04-26
AU2013365908A1 (en) 2015-06-11
US10246433B2 (en) 2019-04-02
RS60582B9 (sr) 2021-09-30
US9040515B2 (en) 2015-05-26
MX2015008058A (es) 2015-10-30
LT3339303T (lt) 2020-09-10
BR112015014678A2 (pt) 2017-07-11
UY35225A (es) 2014-07-31
MY176307A (en) 2020-07-28
ME02980B (fr) 2018-10-20
AP2015008574A0 (en) 2015-07-31
EA201590879A1 (ru) 2015-12-30
EP2935238B1 (fr) 2017-12-27
PH12015501367A1 (en) 2015-09-02
RS56815B1 (sr) 2018-04-30
KR101712441B1 (ko) 2017-03-07
BR112015014678B1 (pt) 2021-12-07
KR20150100823A (ko) 2015-09-02
MX2020002924A (es) 2020-07-22
TWI546293B (zh) 2016-08-21
MD20150052A2 (ro) 2015-12-31
CY1123237T1 (el) 2021-10-29
MY192259A (en) 2022-08-12
ES2808987T9 (es) 2021-11-29
AU2013365908C1 (en) 2018-01-25
PL3339303T3 (pl) 2021-01-25
GEP201706718B (en) 2017-08-10
CA2893339C (fr) 2017-06-13
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
EP3339303B9 (fr) 2021-07-21
IL239520B (en) 2018-05-31
CL2015001733A1 (es) 2015-10-23
EP3339303B1 (fr) 2020-06-24
HRP20201194T2 (hr) 2021-09-17
JP2016507497A (ja) 2016-03-10
CN104870435B (zh) 2016-12-07
IL239520A0 (en) 2015-08-31
NO2961649T3 (fr) 2018-02-17
CU24414B1 (es) 2019-05-03
PT3339303T (pt) 2020-07-30
MD4664B1 (ro) 2019-12-31
PH12015501367B1 (en) 2018-08-03
ES2808987T3 (es) 2021-03-02
UY38712A (es) 2020-06-30
HUE038238T2 (hu) 2018-10-29
ECSP15031579A (es) 2017-08-31
ME03793B (fr) 2021-04-20
HK1208866A1 (en) 2016-03-18
HRP20180060T1 (hr) 2018-02-23
TR201802791T4 (tr) 2018-03-21
LT2935238T (lt) 2018-02-26
US20170233368A1 (en) 2017-08-17
DOP2015000157A (es) 2015-11-30
AR094174A1 (es) 2015-07-15
DK3339303T3 (da) 2020-08-10
MD4664C9 (ro) 2020-07-31
EP2935238A1 (fr) 2015-10-28
WO2014097041A1 (fr) 2014-06-26
CN104870435A (zh) 2015-08-26
AU2013365908B2 (en) 2017-07-20
MA38175B1 (fr) 2018-11-30
ES2658974T3 (es) 2018-03-13
CY1119883T1 (el) 2018-06-27
SI2935238T1 (en) 2018-04-30
US20140179667A1 (en) 2014-06-26
PE20151090A1 (es) 2015-08-07
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
CU20150062A7 (es) 2015-11-27
UA111305C2 (uk) 2016-04-11
TW201446753A (zh) 2014-12-16
TN2015000281A1 (fr) 2016-10-03
HUE050009T2 (hu) 2020-11-30

Similar Documents

Publication Publication Date Title
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA38138A1 (fr) Dérivés inédits de quinolone
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
UA111770C2 (uk) Інгібітори бромдомену
MX2014012695A (es) Derivados de isoindolona.
PH12016501440A1 (en) Novel heterocyclic compounds
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA025302B8 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA38240A1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
UA107455C2 (uk) Похідні індолу як протиракові агенти
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
TR201819805T4 (tr) Flavaglin türevleri̇.
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38679B1 (fr) Modulateurs du récepteur de cxcr7